JAZZ

Jazz Pharmaceuticals, Inc.

240.74

USD

-3.10

-1.27%

Sep 18, 15:59 UTC -4

Closed

After-Market

237.74

-3.00

-1.25%

Jazz Pharmaceuticals, Inc. Profile

About

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.

Info & Links

CEO

Renee D. Gala

Headquarters

FIFTH FLOOR, WATERLOO EXCHANGE, WATERLOO ROAD
DUBLIN, L2 D04 E5W7, IRELAND

Auditor

KPMG

Share holders

878

Employees

2,890

Jazz Pharmaceuticals, Inc. Statistics

Valuation Measures

Market Capitalization²

15.43B

Enterprise Value

18.16B

Enterprise Value/EBITDA(ttm)

11.25

Price to Earnings Ratio(ttm)

10.42

Price to Sales(ttm)

3.40

Price to Book(mrq)

3.25

Price to Cash(ytd)

14.80

Profitability

Gross Margin(ttm)

88.39%

Operating Margin(ttm)

32.50%

Profit Margin(ttm)

20.67%

Return on Equity(ttm)

33.97%

Return on Invested Capital(ttm)

11.06%

Return on Assets(ttm)

13.02%

Income Statement

Revenue(ttm)

4.60B

Revenue Per Share(ttm)

70.88

Gross Profit(ttm)

4.07B

EBITDA(ttm)³

1.61B

Net Income Available to Common(ttm)

940.75M

Diluted EPS(ttm)

14.50

Share Statistics

Beta (5Y Monthly)

0.36

52-Week Change

85.84%

S&P 500 52-Week Change

17.10%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

64.91M

Dividend Yield

0.00%

Float⁴

62.25M

% Held by Insiders

4.10%

% Held by Institutions

89.14%

Balance Sheet

Total Cash(mrq)

2.20B

Total Cash Per Share(mrq)

33.89

Total Debt(mrq)

4.35B

Total Debt/Equity(mrq)

90.62%

Current Ratio(mrq)

1.78%

Quick Ratio(mrq)

1.58%

Book Value Per Share(mrq)

74.10

Cash Flow

Operating Cash Flow Per Share(ytd)

11.87

Free Cash Flow(ytd)

786.10M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.